KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Charles River Laboratories International (CRL) EBIAT (2016 - 2025)

Charles River Laboratories International has reported EBIAT over the past 17 years, most recently at -$278.5 million for Q4 2025.

  • For Q4 2025, EBIAT fell 29.82% year-over-year to -$278.5 million; the TTM value through Dec 2025 reached -$145.5 million, down 749.92%, while the annual FY2025 figure was -$144.3 million, 750.08% down from the prior year.
  • EBIAT for Q4 2025 was -$278.5 million at Charles River Laboratories International, down from $54.4 million in the prior quarter.
  • Over five years, EBIAT peaked at $187.1 million in Q4 2023 and troughed at -$278.5 million in Q4 2025.
  • A 5-year average of $61.9 million and a median of $91.4 million in 2021 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: surged 54.76% in 2022 and later crashed 214.65% in 2024.
  • Year by year, EBIAT stood at $145.4 million in 2021, then increased by 25.64% to $182.7 million in 2022, then rose by 2.39% to $187.1 million in 2023, then crashed by 214.65% to -$214.5 million in 2024, then fell by 29.82% to -$278.5 million in 2025.
  • Business Quant data shows EBIAT for CRL at -$278.5 million in Q4 2025, $54.4 million in Q3 2025, and $52.7 million in Q2 2025.